logo-loader
viewArix Bioscience PLC

Arix Bioscience Plc - Notice of Results

Arix Bioscience Plc - Notice of Results

Arix Bioscience Plc - Notice of Results

PR Newswire

Arix Bioscience plc

Notice of Results

LONDON, 20 August 2019: Arix Bioscience plc (“Arix”, LSE: ARIX) a global venture capital company focused on investing in and building breakthrough biotech companies, will announce its interim results for the six months ended 30 June 2019, on Wednesday, 28 August 2019.

A presentation and webcast for analysts will be held on the day of results at 12:30pm BST at the Devonshire Club, 5 Devonshire Square, London, EC2M 4YD. Details of the webcast will be available on request. The webcast will be recorded, and a replay will be available on the Company's website at https://arixbioscience.com/investor-relations/results-centre

ENDS

Enquiries

For more information on Arix, please contact:

Arix Bioscience plc
Charlotte Parry, Head of Investor Relations
+44 (0)20 7290 1072
[email protected]

Optimum Strategic Communications
Mary Clark, Supriya Mathur
T: +44 (0) 203 950 9144
[email protected]

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors.

For further information, please visit www.arixbioscience.com

Quick facts: Arix Bioscience PLC

Price: 119

Market: LSE
Market Cap: £161.31 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Arix Bioscience acquires stake in novel firm developing sickle cell treatment

Arix Bioscience PLC (LON:ARIX) investment associate John Cassidy talks Proactive London through its decision to invest US$15mln (£11.3mln) in Imara - a firm which is developing treatments for sickle cell disease. Through the deal Arix receives a 10% stake in the company while also...

on 19/3/19